I-Mab and MorphoSys to Test C5aR1 Antibody in the US

Shanghai 's I-Mab and MorphoSys AG of Munich announced they have permission to start US trials of an anti-C5aR1 antibody in patients with advanced solid tumors. The candidate is designed to be used together with checkpoint inhibitors. Two years ago, I-Mab in-licensed greater China rights to the novel antibody in a $105 million agreement. As part of the deal, I-Mab agreed to conduct ex-China trials of the candidate in return for a single-digit royalty on sales outside of China . More details.... Stock Symbols: (NSDQ: IMAB) (FSE: MOR) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.